The main bottlenecks for current DNA detection are specificity, time-to-result, cost and portability.
SnapDNA is developing the next generation, best-of-breed DNA detection platform that can address these limitations using semiconductor-based bio chip detection with direct electrical measurements. Detection has no moving parts and enables a dramatically simplified instrument design that could potentially even operate as an accessory to smartphone.
SnapDNA has demonstrated over an order of magnitude higher specificity with a detection approach that is expected to reduce detection time from hours to a few minutes and enable high margin tests even at the most aggressive sales prices. All proprietary technology is being developed entirely in house allowing for multiple highly defensible patents on DNA detection and bio-chip analysis.
In addition, SnapDNA has access to portions of $50M non-dilutive R&D through a USDA CRADA (Cooperative Research and Development Agreement). Under the CRADA, USDA will co-develop and validate foodborne pathogen tests specifically for the SnapDNA platform. SnapDNA tests are expected to be validated for use by USDA and FDA inspectors before launch, which will provide the company with a significant market advantage.